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Purpose: The use of intravenous golimumab (GLM-
IV), in combination with methotrexate, was approved
by the US Food and Drug Administration in July 2013
for the treatment of moderate to severe, active rheu-
matoid arthritis (RA). GLM-IV is available in 50-mg
vials, and the prescribing information speciﬁes a
dosing regimen of 2 mg/kg at 0 and 4 weeks and then
every 8 weeks thereafter. The purpose of this study
was to examine the patterns of prescribing and
administration of GLM-IV, including the demo-
graphic, clinical, and utilization characteristics of
patients with RA newly treated with GLM-IV.
Methods: Rheumatology practices across the con-
tinental United States were solicited for a chart-review
study. Inclusion criteria were: (1) diagnosis of RA; (2)
current treatment with GLM-IV; (3) age Z18 years;
and (4) lack of pregnancy (in female patients). Physi-
cians were offered a monetary incentive for each
eligible chart provided. An electronic case-report
form was developed to aid in the chart data extra-
ction and included ﬁelds for demographic character-
istics, available comorbid diagnoses, prior RA
treatments, and doses and dates of GLM-IV
administration.
Findings: A total of 117 eligible patient charts from
15 rheumatologist practices were reviewed. The pa-
tient sample was predominantly female (81.2%), with
a mean (SD) age of 55.4 (14.5) years. A total of
55.6% of patients had evidence of biologic treatment
before receiving GLM-IV, and 53% had at least 1
comorbid condition. In total, 300 individual GLM-IV
infusions from this sample were reviewed. Due to the
relatively recent approval of GLM-IV use by the US
Food and Drug Administration, the majority of
patients in this sample (69.2%) had received only
between 2 and 4 infusions at the time of the review.
For infusion records with valid dose data, the mean
number of administered vials was 3.6 (0.8) (total dose,2028180 mg); the majority of patients received a dose
consistent with the prescribed dose of 2 mg/kg.
Combination therapy with methotrexate was ob-
served in the charts of a minority of patients
(27.4%). The mean interval between induction and
the ﬁrst follow-up infusion was 32.9 (11.4) days, with
a mean maintenance interval of 56.5 (13.3) days.
Implications: This analysis provides an early
glimpse of the patterns of prescribing GLM-IV. Over-
all, patients appeared to have been receiving GLM-IV
in accordance with Food and Drug Administration
labeling; although the rate of prescribing methotrexate
was low, dosages and administration intervals were
within the expected ranges. (Clin Ther.
2015;37:2028–2036) & 2015 The Authors. Published
by Elsevier HS Journals, Inc.
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venous golimumab, rheumatoid arthritis.INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease
characterized by inﬂammation of the joints and
surrounding tissues, and affects approximately 1%
of the global population.1 Treatment for RA is
focused on reducing and controlling the inﬂammation
that drives tissue damage and disease progression.
Historically, disease-modifying antirheumatic drugs
(DMARDs) have been the mainstay of RA treatment.
However, over the past decade, the treatment of RA
has improved signiﬁcantly with the introduction of
biologic DMARDs. These biologic therapies speciﬁcally
target and neutralize proinﬂammatory cytokines andVolume 37 Number 9
B.L. Brady et al.suppress immune-cell activation.2 The ﬁrst biologics
targeted tumor necrosis factor (TNF)-α, and now
make up the primary class of biologics used for
treating RA; biologics with other mechanisms of
action, targeting different pro-inﬂammatory cytokines
and immune-cell activation, are also available
and typically are used after nonresponse with
anti-TNF agents.3 Because RA is a chronic disease,
and because biologic medications may lose efﬁcacy
over time, some patients are prescribed multiple
biologics over the course of the disease. Switches
between biologic agents occur both within the
anti-TNF class and across other mechanisms of
action.4–7
Each biologic medication has a unique dosing
regimen. Biologics may or may not include an in-
duction period and range from daily administration to
administration once every 8 weeks.8–17 Biologic med-
ications must be administered parenterally and are
available as subcutaneous and/or intravenous formu-
lations. Although the route of administration (ROA)
has been reported not to affect the efﬁcacy of biologic
medications, dosing regimens, as well as a patient’s
preference for and comfort with a speciﬁc ROA,
may affect medication adherence and treatment
efﬁcacy.18–23 In some cases, patients and providers
are most comfortable with the medications and the
ROAs with which they have experience, whereas
for others, particular aspects of treatment, such as
medical oversight of intravenous administration or
at-home administration of subcutaneous formula-
tions, drive preferences.20,22,24
In July 2013, the US Food and Drug Administra-
tion (FDA) approved the use of intravenous golimu-
mab (GLM-IV), in combination with methotrexate,
for the treatment of moderate to severe, active RA.13
GLM-IV is a fully human monoclonal antibody
speciﬁc for human TNF-α and is administered as 2
mg/kg IV infused over 30 minutes at weeks 0 and 4
(induction) then every 8 weeks thereafter (mainte-
nance).25 Although anti-TNF biologics are the class of
biologic DMARDs most commonly used for the
treatment of RA, GLM-IV is only the second intra-
venously administered anti-TNF biologic approved
for the treatment of RA. In contrast, 4 of the 6 anti-
TNF biologics approved for the treatment of RA are
administered subcutaneously.
The primary purpose of this study was to examine
the early patterns of prescribing and administration ofSeptember 2015GLM-IV in patients with RA through a review of
patients’ charts; secondary study end points included
assessments of the demographic and clinical character-
istics of patients newly prescribed GLM-IV. Analyses
focused on how the observed GLM-IV prescribing
patterns compared with recommended guidelines, and
on patients’ history of biologic medications.MATERIALS AND METHODS
Study Sites
This study was limited to rheumatologists prac-
ticing in the United States. Among these practi-
tioners, a subset of those who prescribed GLM-V
were identiﬁed and contacted by telephone to
determine whether they were eligible and willing to
participate in the study. Rheumatologists who
agreed to participate and who had prescribed
GLM-IV to at least 1 patient were then recruited
into the study. All providers were offered an initial
incentive of $400 for agreeing to participate and an
additional $50 for every chart identiﬁed as eligible
for review. To be included in the study, providers
were required to complete study contracting and to
provide at least 1 eligible patient chart. Of the 300
sites contacted, 15 providers’ practices across 12
states participated in the study (Table I). Contracted
providers were not asked about prior participation
in clinical trials of biologic DMARDs. Appropriate
institutional review board approval was obtained
from Essex IRB (Lebanon, New Jersey) before the
recruitment of providers and before the review of
patients’ charts.
Inclusion/Exclusion Criteria
To be included in the study, patients’ charts were
required to have had evidence of a diagnosis of RA
and at least 1 infusion of GLM-IV. Additionally,
inclusion was limited to patients at least 18 years of
age. Charts of pregnant female patients were not
included in this study.
Data Collection
A database (Access; Microsoft Corp., Redmond,
Washington) was developed as the case-report form
and was designed to mimic a Web page interface for
ease of data entry. Data-entry forms were separated
into subject tabs and included patients’ characteristics,
comorbidity data, GLM-IV data, combination therapy2029
Table II. Patient characteristics (N ¼ 117). Data
are given as numbers (%) of patients
unless otherwise noted.
Characteristic Value
Demographics
Age, mean (SD), y 55.4 (14.5)
Female 95 (81.2)
Ethnicity
White 38 (32.5)
Black 6 (5.1)
Hispanic 2 (1.7)
Other 1 (0.9)
Data unavailable 70 (59.8)
Insurance type
Unavailable 80 (68.4)
Commercial 23 (19.7)
Medicare 13 (11.1)
Government 1 (0.9)
Major comorbidities
Hypertension 26 (22.2)
Depression 23 (19.7)
Hyperlipidemia/
hypercholesterolemia
19 (16.2)
Musculoskeletal disorder 18 (15.4)
Diabetes mellitus 12 (10.3)
Cardiovascular disease 7 (6.0)
Other autoimmune disorder 4 (3.4)
Table I. Numbers of patient medical records
provided by physicians (n ¼ 23 physi-
cians from 15 sites).
No. of Charts
No. of Physicians
Providing Charts
1 8
2 3
3 1
4 2
5 1
6 1
7 1
8 1
10 1
11 1
12 1
14 1
19 1
Clinical Therapeuticsadministered with GLM-IV, and previous RA
treatments. Speciﬁc variables associated with GLM-
IV infusions included date of administration, admin-
istered quantity, and patients’ weight. Of the 15
provider practices that agreed to participate in the
study, 12 directly transferred patients’ charts and 3
required on-site data abstraction. Six research staff
members, each trained in the privacy laws and general
research ethics of the Health Insurance Portability and
Accountability Act, performed the chart review and
data abstraction. In total, 117 eligible charts from RA
patients were reviewed. Chart composition varied
markedly across patients and sites, with the review
of a single chart taking a mean duration of 60
minutes. Chart information dating back a maximum
of 5 years from the most recent GLM-IV infusion was
extracted.Data Analysis
The dataset resulting from the chart review was
analyzed. Descriptive statistics, including means (SD)
and frequencies (%) of the characteristics of the patients
and of the GLM-IV administrations are presented. For
those patients with evidence of prior biologic use,
descriptive statistics for the number, medication, and
ROA of prior treatments were also calculated.2030RESULTS
Patients included in this study were predominantly
female (n ¼ 95 [81.2%]), with a mean age of 55.4
(14.5) years (Table II). Data on ethnicity and
insurance type were not present in the charts from a
majority of the patients (59.8% and 68.4%,
respectively). Based on available ethnicity and
insurance data, the sample was composed of 38 white
patients, 6 black, 2 Hispanic, and 1 designated as
"other"; commercial insurance was the most common
coverage type (23), followed by Medicare (13).
Regarding comorbidities, 22.2% of the sample had
documented evidence of a comorbid diagnosis of
hypertension; 19.7%, depression; and 16.2%,
hyperlipidemia/ hypercholesterolemia (Table II).
Among the 117 patients in the sample, 300 indi-
vidual GLM-IV infusions were identiﬁed, with theVolume 37 Number 9
Table III. Intravenous golimumab treatment (N
¼ 117 with a total of 300 GLM-IV
infusions).
Parameter Value
Patient weight at infusion, mean
(SD), kg
83.2 (22.1)
Infusion characteristics
Vials administered per infusion,
mean (SD)
3.6 (0.8)
Induction interval, mean (SD), min 32.9 (11.4)
Maintenance interval, mean (SD),
min
56.5 (13.3)
Infusions per patient, no. (%) of patients
1 25 (21.4)
2 38 (32.5)
3 29 (24.8)
4 14 (12.0)
5 10 (8.5)
6 1 (0.9)
Combination therapy with methotrexate, no. (%)
of patients
Yes 32 (27.4)
No, with documentation of prior
issues with methotrexate
15 (12.8)
No, without any documentation 70 (59.8)
B.L. Brady et al.majority of patients (92 [78.6%]) receiving o4
infusions at the time of the review (Table III).
Infusion records suggested that most patients
received the correct number of vials to yield a
prescribing dose of 2 mg/kg, with a mean of 3.6
(0.8) vials administered (dose, 180 mg). Record
keeping differed across providers, with some
recording the number of vials infused (with or
without a wasted amount), others providing the dose
administered in milligrams, and some providers
recording both. In cases in which an incorrect
number of vials was administered, the reason was a
minor discrepancy between the recommended dose
and the vial contents (50 mg), and the dose tended to
be slightly low to avoid the use of another vial. For
example, a patient whose prescribed dose at 2 mg/kg
was 104 mg may have been administered 2 vials (dose,
100 mg). The mean interval between induction and
the ﬁrst follow-up infusion was 32.9 (11.4) days, withSeptember 2015a mean maintenance interval of 56.5 (13.3) days.
Combination therapy with GLM-IV and methotrexate
was reported in 27.4% of patients’ charts. Another
12.8% of patients had documentation that they were
unable to tolerate methotrexate, leaving 59.8% of
patients with no accessible documentation of having
received combination with methotrexate (Table III).
Table IV to Table VI display data on previous
biologic use among the sample. Sixty-ﬁve patients
(55.6%) had evidence of having received biologic
treatment preceding GLM-IV initiation (Table IV).
The majority of these patients (46 [70.8%]) had a
single biologic on record. Within the biologic-
experienced group, the most commonly utilized bio-
logics were inﬂiximab (26 [40.0%]), adalimumab (20
[30.8%]), and etanercept (17 [26.2%]). The least-used
biologics were rituximab, tocilizumab, and subcuta-
neous golimumab (Table IV). These rates of market
uptake are consistent with those from other studies,
as adalimumab, etanercept, and inﬂiximab are the
anti-TNF therapies most commonly prescribed ﬁrst-
line.4,26,27 Regarding biologic ROA, 41.5% of pa-
tients had received only subcutaneously administered
treatments, 21.5% had received only infusible treat-
ments, and 20.0% had received a combination of
subcutaneous and infusible treatments before initiat-
ing treatment with GLM-IV (Table IV). The
remaining patients had evidence of either abatacept
or tocilizumab administration in their records, both of
which are available in subcutaneous and intravenous
formulations and therefore could not be assigned to a
particular ROA.
DISCUSSION
The ﬁndings from this study provide a glimpse of the
early prescribing patterns of GLM-IV. On the whole,
the demographic characteristics of this sample of
GLM-IV users were similar to those of the overall
population with RA—primarily female and of middle
age.1,28 The most commonly reported comorbidities
were hypertension (22.2%), depression (19.7%), and
hyperlipidemia/hypercholesterolemia (16.2%), consis-
tent with those from previous reports of the RA
population.29,30 Most patients initiating GLM-IV
had used a biologic earlier in their treatment
(55.6%), although GLM-IV was being used as a
ﬁrst-line biologic therapy in 44.4% of the sample
population. The rate of prior biologic use in this
sample of patients with RA who used GLM-IV was2031
Table IV. Prior biologic use. Data are given as
numbers (%) of patients unless
otherwise noted.
Parameter Value
All patients (N ¼ 117)
Prior biologics used, mean (SD) 1.65 (1.20)
No. of prior biologics on record 65 (55.6)
1 46 (39.3)
2 5 (4.3)
3 9 (7.7)
4 3 (2.6)
5 1 (0.9)
6 0
7 1 (0.9)
Prior biologics used (n ¼ 65)*
Biologic
Inﬂiximab 26 (40.0)
Adalimumab 20 (30.8)
Etanercept 17 (26.2)
Abatacept 15 (23.1)
Certolizumab 13 (20.0)
Golimumab 7 (10.8)
Tocilizumab 7 (10.8)
Rituximab 2 (3.1)
Administration route history
Subcutaneous only 27 (41.5)
Infusions only 14 (21.5)
Combination of known routes 13 (20.0)
Combination including
unknown routes
4 (6.2)
Unknown† 7 (10.8)
*Because some patients received 41 biologic, the total
percentages exceed 100%.
†Because abatacept and tocilizumab are available in
both subcutaneous and infusible formulations, these
were coded as “unknown.”
Clinical Therapeuticssimilar to the rate of prior biologic use reported in
patients who received subcutaneous GLM.28 There
were no differences in sex or age between the subsets
of biologic-experienced and biologic-naïve patients
included in this chart review.
The proportion of patients who were biologic naïve
before taking GLM-IV was higher than expected at
the outset of the study, as GLM-IV was recently2032approved in July 2013. Of the 117 charts examined,
52 did not have evidence of prior biologic use. As the
chart review looked back only 5 years, a deﬁnitive
statement regarding patients’ previous experience with
biologics cannot be made and may have partially
accounted for the high percentage of biologic-naïve
patients observed in this study. There are several
reasons that could lead to the ﬁrst-line prescribing of
this anti-TNF biologic DMARD. First, although the
intravenous formulation is new, the drug itself is not
entirely new. The use of the subcutaneous formulation
of golimumab was approved in April 2009. Therefore,
it is possible that providers are more comfortable with
GLM-IV than they would be with an entirely new
pharmaceutical. Furthermore, GLM-IV and inﬂiximab
are the only 2 intravenous anti-TNF inhibitors, and
the lack of choice compared with the subcutaneous
anti-TNF inhibitor market could have accounted for
the increased use of GLM-IV in biologic-naïve pa-
tients. Many of the providers who participated in the
study had an infusion center on-site, which has been
reported to be associated with the increased use of
infusible biologics.27 The propensity of the contracted
providers to try their patients on new medications was
not assessed in this study, but providers hesitant to
prescribe new medications would likely not have been
included in this study because of the requirement of
having treated at least 1 patient with GLM-IV.
In the cohort of biologic-experienced patients, the
use of a single prior biologic predominated. In this
group of 46 individuals who had used 1 prior biologic,
inﬂiximab was the most commonly cited treatment,
used by 30.4% (Table V). This ﬁnding might suggest a
preference for intravenous administration in a subset of
this sample, as inﬂiximab is the only other intravenous
anti-TNF biologic available.31 In the majority of the
sample with single prior biologic use (54.3%), GLM-IV
was switched from a subcutaneous medication. In
another 7 individuals (15.2%), GLM-IV was switched
from tocilizumab or abatacept, each of which is
available in both subcutaneous and intravenous for-
mulations, placing the percentage of patients remaining
with the intravenous ROA between 30.4% and 45.6%
(Table V). In this sample of 46 patients who had used
one prior biologic, the rate of biologic use did not follow
the rates of market penetration, with certolizumab being
used more frequently than etanercept, one of the most
commonly prescribed ﬁrst-line anti-TNF therapies.4,26,27
The use of certolizumab at such a high rate, as well asVolume 37 Number 9
Table V. Prior biologics used. Data are given as
numbers (%) of patients.
Biologic ROA
Single Prior
Biologic
(n ¼ 46)
Multiple Prior
Biologics
(n ¼ 19)
Inﬂiximab IV 14 (30.4) 12 (63.2)
Adalimumab SC 10 (21.7) 10 (52.6)
Certolizumab SC 7 (15.2) 6 (31.6)
Abatacept IV/SC 5 (10.9) 10 (52.6)
Etanercept SC 4 (8.7) 13 (68.4)
Golimumab SC 4 (8.7) 3 (15.8)
Tocilizumab IV/SC 2 (4.3) 5 (26.3)
Rituximab IV 0 2 (10.5)
ROA ¼ route of administration.
B.L. Brady et al.the ﬁrst-line use of tocilizumab, were unexpected and
may suggest prior use of other biologic agents before the
start of the 5-year chart-review period.
Although ROA does not appear to have been the
driving force behind the choice of GLM-IV in this
sample, as less than half of the patients were switched
from an intravenous biologic, there was still a clear
preference for the intravenous ROA in a subset of
these patients. The switch to GLM-IV in itself may
also suggest a patient’s or provider’s preference for IV
administration in certain cases, as there are several
subcutaneous anti-TNFs that can be prescribed after
nonresponse to a ﬁrst-line treatment. The move to an
intravenous therapy on nonresponse to a subcutaneousTable VI. Route of administration (ROA) of prior biologi
otherwise noted.
ROA
Single Prior Biologic
(n ¼ 46)
SC 25 (54.3)
IV 14 (30.4)
Unknown 7 (15.2)
*Episode of care was deﬁned as the use of a biologic by an indivi
September 2015biologic could be linked to a belief that intravenous
administration can provide a more personalized dose
than subcutaneous administration because the dose can
be exactly matched to a patient’s weight, or a desire to
more closely monitor a patient’s adherence to a
medication regimen because intravenous medications
are administered in the physician’s ofﬁce. A patient’s
perception of increased safety has also been reported
with intravenous administration, due to the increased
involvement of medical professionals in the process,
and may be a factor in providers’ and patients’
decisions.20,24,32 Lastly, providers who offer, and can
bill for, infusion services have been shown to have a
preference for the intravenous ROA.27 Further study of
the motivations regarding the choice of a speciﬁc
biologic, on the part of both the physician and the
patient, is warranted.
There was also an increased rate of subcutaneous
biologic use by the sample of patients who had used
2 or more biologics previously (n ¼ 19). Of these
patients, all had prior use of at least 1 subcutaneous
anti-TNF biologic, with etanercept being the most
commonly used (Table V). The majority of these
patients (13 of 19) also had experience with an
intravenous biologic; again, inﬂiximab was the most
common. There were no patients who used exclusively
intravenous biologics before starting treatment with
GLM-IV, but this is likely in part due to the scarcity of
IV anti-TNF biologics, because individuals using 2
prior biologics had experience only with anti-TNFs.
The use of biologics with other mechanisms of action
by patients with documented previous use of Z2
biologics occurred after the trial of at least 1 anti-
TNF biologic. In some patients with prior use ofcs. Data are given as numbers (%) of patients unless
Multiple Prior Biologics
% of Patients
(n ¼ 19)
% of Episodes of Care*
(n ¼ 61 Total Episodes)
32 (168.4) 32 (52.5)
14 (73.7) 14 (23.0)
15 (78.9) 15 (24.6)
dual.
2033
Clinical Therapeuticsmultiple biologics, anti-TNFs were observed both
before and after the use of biologics with alternative
mechanisms of action. In all individuals who used 3 or
more biologics in the previous 5 years, treatment had
been switched at some point to a biologic with an
alternative mechanism of action.
Overall, the dose and administration of GLM-IV
were in accordance with FDA-approved labeling,
although the rates of GLM-IV use in combination with
methotrexate were low. In general GLM-IV was dosed
at a level consistent with the 2-mg/kg recommended
dose. In some cases, the dose administered was slightly
less than 2 mg/kg, most often due to the dose having
just exceeded that which could be achieved using a
whole number of vials. In all but 3 of these cases, the
recorded doses were within 10% of dose by weight.
Documentation of combination therapy with metho-
trexate, as included in the GLM-IV label, was only
found for 40.2% of patients. Approximately one third
of patients (27.4%) were receiving GLM-IV in combi-
nation with methotrexate, as included in the GLM-IV
labeling; 12.8% of patients were not, with an intoler-
ance to methotrexate documented in their charts. No
documentation regarding methotrexate was available
in the remaining 59.8% of charts. Although combina-
tion therapy is known to be used at lower rates than
recommended, the use of GLM-IV and methotrexate
by one third of patients is still lower than expected.27,33
Due to the proximity in time of the chart collection and
GLM-IV approval (July 2013), most patients were
early in their treatment regimens, with over half of
patients (53.8%) still in the induction dosing phase
(2 infusions over a period of 4 weeks). The majority of
the patients in the maintenance phase of treatment had
received 3 infusions, with only 21.4% of patients
having received 4 or more infusions (Table III).
Although chart review can provide a comprehen-
sive assessment of a patient’s clinical characteristics
and disease treatment history, not all aspects of a
patient’s care regimen can be assessed through these
means, especially considering the fragmented nature
of the health care system. This study reviewed rheu-
matologists’ charts for the assessment of the character-
istics of patients with RA and their treatment histories.
As rheumatologists are specialists who treat a speciﬁc
aspect of a patient’s overall health care needs, all of
the patients reviewed here were likely to have been
seeing another physician for their general health care;
patients may have also seen multiple rheumatologists2034over their course of disease. The level of communica-
tion between these providers remains unknown, and it
is possible that charts from the practices of primary
care physicians and rheumatologists would shed
different light on the same patient. Therefore, the full
picture of a patient’s health care and treatment
strategy may not be available from the review of a
single chart. In addition, chart documentation varies
dramatically among providers and practices, resulting
in varying levels of information and detail in each
chart. For example, the lack of patient demographic
data available in this study may have been, in part,
due to chart documentation; the low rates of GLM-IV
administration in combination with methotrexate may
also have been affected by differences in documenta-
tion across various providers. Lastly, charts are
intended as a tool for providers to use in the ongoing
assessment of a patient’s clinical status and disease
progression. Therefore, the patient’s perspective is
generally not available, leading to only a provider’s
assessment of the patient’s disease state and quality
of life.
This study reviewed early GLM-IV use in a
population of patients with RA newly initiated on
treatment with GLM-IV. The information on dose
and administration and patients characteristics
collected suggest GLM-IV prescribing and adminis-
tration in accordance with the FDA-approved
labeling in this heterogeneous sample of patients
with RA. Just under half of GLM-IV users were
biologic naïve; biologic-experienced patients had
used between 1 and 7 prior biologics. Most patients
were early in their treatment plans, likely due to the
close timing of the chart review in relation to the
approval of GLM-IV. The rate of GLM-IV admin-
istration in combination with methotrexate was low
in this population, but patients generally received a
dose of 2 mg/kg of GLM-IV, consistent with FDA-
approved labeling. This study is the ﬁrst to report on
GLM-IV users’ characteristics via chart review.
Follow-up studies on the patterns of prescribing
and administration GLM-IV, after it has been
available for a longer period and after physicians
and patients have become more familiar with the
medication, are warranted.
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